LXG

LexaGene Files for Chapter 7 Bankruptcy

Retrieved on: 
Friday, February 24, 2023
Bankruptcy, LXG, United States bankruptcy court, Chapter 7, Title 11, United States Code, TSX Venture Exchange, File, OTCQB, Security (finance)

BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code.

Key Points: 
  • BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code.
  • The filing, which took place earlier today at the U.S. Bankruptcy Court for the District of Massachusetts, located in Boston, Massachusetts, will result in federal appointment of a bankruptcy trustee to liquidate the Company’s assets and distribute any proceeds.
  • Dr. Jack Regan, LexaGene’s CEO and founder, stated, “Despite our best efforts, we were unable to secure the necessary funding to continue our operations.
  • Accordingly, the board of directors has exercised its business judgment to commence liquidation proceedings for the Company.

LexaGene Provides Update on BioPharma Sector

Retrieved on: 
Wednesday, February 8, 2023
Area studies, RNA, Genetic testing, Minute virus of mice, Advertising, R, CDMO, LXG, Vesivirus, MVM, DC, Common, Escherichia coli, OTCQB, Mycoplasma, Partnership, Organization, Bacteria, Vaccine, Cryptocurrency, Fine chemical, Mouse

Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a leading Contract Drug Manufacturing Organization (CDMO) with a market cap that is >$40B.

Key Points: 
  • Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a leading Contract Drug Manufacturing Organization (CDMO) with a market cap that is >$40B.
  • During our conversations with our traditional biopharma customer, they suggested presenting at the 2023 National Institute for Innovation in Manufacturing Biopharmaceuticals (“NIIMBL”) National Meeting being held in June in Washington, DC.
  • NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical innovation and advance other industry objectives.
  • This exposure will help LexaGene achieve better brand awareness and wider adoption in the industry.”
    For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers

Retrieved on: 
Wednesday, January 18, 2023
Genetic testing, News, Culture, Risk, Interplanetary contamination, PCR, Mycoplasma, OTCQB, LXG, Fine chemical

We’ve communicated this achievement, plus other development milestones, to our biopharma customers, who have in turn expressed great enthusiasm."

Key Points: 
  • We’ve communicated this achievement, plus other development milestones, to our biopharma customers, who have in turn expressed great enthusiasm."
  • At these latter stages, often 10’s of millions of dollars’ worth of product is at risk should a contamination be detected.
  • The data generated for this feasibility study demonstrates LexaGene’s MiQLab System can be easily configured for extremely sensitive applications such as detecting Mycoplasma.
  • I will share updates as they become available.”
    For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .

LexaGene Successfully Completes Statement of Work for BioPharma Company

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Staphylococcus, LXG, Streptococcus, Escherichia coli, Risk, TSX Venture Exchange, Legislation, System, Gold, PCR, SEDAR, News, Genetic testing, Mycoplasma, OTCQB, Safety, Medical device, Cryptocurrency, Risk management, Cutibacterium

Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.

Key Points: 
  • Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.
  • The study was conducted mainly at LexaGene except for using proprietary materials from the biopharma company, as these tests were performed by employees of the biopharma company at their location using their recently purchased MiQLab System.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers.

LexaGene Closes Secured Convertible Note Transaction

Retrieved on: 
Tuesday, November 1, 2022
PCR, SEDAR, News, Regulation, System, Exercise, GLOBE, LLC, Intention, TSX Venture Exchange, Securities Act of 1933, Technology, USD, Company, The Note, Note, OTCQB, LXG, Security (finance), Cryptocurrency

BEVERLY, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. ,( OTCQB: LXXGF ; TSX-V: LXG ) (LexaGene or the Company), a molecular diagnostics company that has commercialized the MiQLab System for automated multiplex PCR testing, announces that it has issued a 12% secured convertible note (the Note) to Meridian LGH Holdings 2, LLC, an affiliate of an insider of the Company, in the aggregate principal amount of up to USD$1,600,000.

Key Points: 
  • BEVERLY, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. ,( OTCQB: LXXGF ; TSX-V: LXG ) (LexaGene or the Company), a molecular diagnostics company that has commercialized the MiQLab System for automated multiplex PCR testing, announces that it has issued a 12% secured convertible note (the Note) to Meridian LGH Holdings 2, LLC, an affiliate of an insider of the Company, in the aggregate principal amount of up to USD$1,600,000.
  • The Note is secured against the assets of the Company and is guaranteed by the subsidiaries of the Company.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter or LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers.

Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation

Retrieved on: 
Thursday, October 20, 2022
News, LinkedIn, Time, Culture, Virus, Fungus, Twitter, System, LXG, Technology, Plant, PCR, Company, TSX Venture Exchange, Intention, Genetic testing, GLOBE, OTCQB, Solution, SEDAR, Fine chemical, Cryptocurrency

Dr. Jack Regan, LexaGenes CEO and Founder stated, The technology validation study outlined within the signed statement of work will provide this biopharma company much of the data they need to make future decisions in just a few weeks of time.

Key Points: 
  • Dr. Jack Regan, LexaGenes CEO and Founder stated, The technology validation study outlined within the signed statement of work will provide this biopharma company much of the data they need to make future decisions in just a few weeks of time.
  • This company has agreed to have the validation work done at LexaGene, and they will have a scientist embedded onsite during parts of the study.
  • The biopharma company will provide some bio-reactor samples that are required for the study.
  • Dr. Regan concluded, Single manufacturing plants of large biopharma manufacturers generate product worth hundreds of millions of dollars every year.

LexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab System

Retrieved on: 
Thursday, October 13, 2022
Adoption, News, LinkedIn, Sale, Twitter, System, LXG, 10B, Technology, PCR, Company, Industry, TSX Venture Exchange, Intention, Optimism, Genetic testing, GLOBE, OTCQB, Solution, SEDAR, Fine chemical, Risk management, Cryptocurrency

Dr. Jack Regan, LexaGenes CEO and Founder stated, We are excited to report a major international biopharma manufacturer has provided us a signed quote for the purchase of a MiQLab System.

Key Points: 
  • Dr. Jack Regan, LexaGenes CEO and Founder stated, We are excited to report a major international biopharma manufacturer has provided us a signed quote for the purchase of a MiQLab System.
  • Weve also discussed assisting them in their validation to speed up the timeline for determining whether the MiQLab System will meet their significant manufacturing testing needs.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter or LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers.

LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California

Retrieved on: 
Thursday, September 1, 2022
Urinary tract infection, Technology, LXG, Genetic testing, Sale, American Animal Hospital Association, Connected relation, TSX Venture Exchange, LinkedIn, PCR, GLOBE, Intention, Conference, Company, News, Twitter, Annual conferences, System, SEDAR, OTCQB, Pharmaceutical industry, Cryptocurrency

Dr. Jack Regan, LexaGenes CEO and Founder stated, We are pleased to close our first sale following Dr. Jane Sykes webinar on the utility of using the MiQLab System for diagnosing urinary tract infections.

Key Points: 
  • Dr. Jack Regan, LexaGenes CEO and Founder stated, We are pleased to close our first sale following Dr. Jane Sykes webinar on the utility of using the MiQLab System for diagnosing urinary tract infections.
  • We will continue to build momentum from this webinar as we demonstrate the value of the MiQLab System in our upcoming shows.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter or LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers.